The proven benefits of peptides come from approved peptide drugs. Semaglutide (Wegovy) cut body weight by 14.9% versus 2.4% on placebo in a 1,961-person trial (STEP 1) and lowered the risk of heart attack, stroke or cardiovascular death by 20% in another (SELECT); teriparatide (Forteo) cut new spine fractures from 14% to 5% (Neer 2001). Research peptides sold online, such as BPC-157, are not FDA-approved, and their best evidence is animal studies.
| Item | Status |
|---|---|
| US FDA status | Approved: semaglutide (Wegovy), tirzepatide (Zepbound), teriparatide (Forteo), tesamorelin (Egrifta), afamelanotide (Scenesse), bremelanotide (Vyleesi). Not approved: BPC-157, TB-500, MOTS-c, GHK-Cu injections (USADA on BPC-157) |
| Compounding | BPC-157, TB-500 and MOTS-c were withdrawn from FDA’s Category 2 (FDA); the advisory committee voted for 503A listing on 2026-07-23 (BPC-157 and TB-500 8–6 with 1 abstention, MOTS-c 7–5 with 2, as reported by trade press; meeting page); advisory, no FDA rule yet |
| WADA 2026 | BPC-157 banned under S0; TB-500 and tesamorelin under S2; MOTS-c under S4 (WADA 2026 List); GLP-1 drugs not prohibited (USADA) |
| WADA 2027 | From 2027-01-01 “peptides” in general are named under S0; semaglutide and tirzepatide stay in the monitoring program, not prohibited (USADA) |
| Strongest evidence | Approved label and large Human RCTs for the six approved drugs; small Human RCTs for oral collagen peptides; Animal for BPC-157, TB-500 and MOTS-c |
| Human trials | SELECT (n=17,604) and other phase 3 trials for approved drugs; BPC-157: 3 registered, none with posted results (NCT02637284, NCT07752381, NCT07803250); MOTS-c: 1 registered, of the analog CB4211, completed, no results posted (NCT03998514) |
| Last checked | 2026-10-18 (status sources re-verified 2026-10-13) |
Key points:
- Peptide drugs approved for narrow uses show clear benefits in their trials: more pain-free sunlight time for a light-sensitivity skin disease, more sexual desire in premenopausal women, less abdominal fat in HIV lipodystrophy.
- Collagen peptides, sold as supplements, improved skin elasticity in one 69-woman trial and knee pain scores in an 11-trial meta-analysis, though one 167-person trial found no effect on knee pain.
- BPC-157’s best human data are a 16-patient knee-pain chart review without a control group.
- Thymosin alpha-1 did not lower deaths in a 1,106-patient sepsis trial.
- In an August 2026 warning letter, FDA called one seller’s “research use only” semaglutide, PT-141 and tesamorelin products unapproved new drugs.
Benefits of peptides at a glance
| Peptide | Evidence and status | Best result |
|---|---|---|
| Semaglutide (Wegovy) | Approved; Human RCT, n=17,604 | SELECT: heart events 6.5% vs 8.0% |
| Tirzepatide (Zepbound) | Approved; Human RCT, n=2,539 | SURMOUNT-1: −20.9% weight (15 mg) vs −3.1% |
| Teriparatide (Forteo) | Approved; Human RCT, n=1,637 | Neer 2001: new spine fractures 5% vs 14% |
| Tesamorelin (Egrifta) | Approved; Human RCT, n=404 | Falutz 2010: visceral fat −10.9% vs −0.6% |
| Afamelanotide (Scenesse) | Approved; Human RCT, n=94 | Langendonk 2015: 69.4 vs 40.8 pain-free hours in sun |
| Bremelanotide (Vyleesi) | Approved; Human RCTs, n=1,267 | Kingsberg 2019: desire score +0.35 vs placebo |
| Collagen peptides (oral) | Supplement; Human RCTs | Simental-Mendía 2025: lower knee OA pain, 11 RCTs |
| Thymosin alpha-1 | Human RCT, n=1,106 | TESTS: sepsis deaths 23.4% vs 24.1%, no difference |
| GHK-Cu (topical) | Topical; small Human RCT | Miller 2006: no objective skin difference |
| BPC-157 | Not approved; Animal, 1 case series | Vasireddi 2025: 35 of 36 studies preclinical |
| TB-500 | Not approved; Animal | Biçer 2026: stronger healed rat tendons |
| MOTS-c | Not approved; Animal | Lee 2015: prevented diet-induced obesity in mice |
Benefits of approved peptide drugs
Peptides are short chains of amino acids; afamelanotide, for example, is “a synthetic peptide containing 13 amino acids” (Scenesse label). The peptides with proven benefits are the ones FDA has approved, each for a specific use backed by randomized trials.
Weight and heart (semaglutide, tirzepatide). In STEP 1, adults without diabetes lost 14.9% of body weight on semaglutide versus 2.4% on placebo over 68 weeks [Human RCT, n=1,961] (Wilding 2021). In SELECT, among 17,604 people with heart disease and overweight or obesity but no diabetes, heart attack, stroke or cardiovascular death occurred in 6.5% on semaglutide versus 8.0% on placebo, a hazard ratio of 0.80 [Human RCT] (Lincoff 2023), and Wegovy’s label now includes that use (Wegovy label). Tirzepatide, approved as Zepbound in 2023 (FDA), produced a 20.9% weight loss in its 15 mg arm versus 3.1% at 72 weeks [Human RCT, n=2,539] (SURMOUNT-1). The newer weight-loss peptides are compared in retatrutide vs tirzepatide vs semaglutide.
Bone (teriparatide). Teriparatide is a parathyroid hormone analogue, PTH 1-34 (Forteo label). In 1,637 postmenopausal women with earlier spine fractures, new spine fractures occurred in 14% on placebo versus 5% and 4% on the two doses, over a median 21 months [Human RCT] (Neer 2001).
Abdominal fat in HIV (tesamorelin). Tesamorelin, a growth-hormone-releasing factor analogue, reduced visceral fat by 10.9% versus 0.6% on placebo over six months in 404 patients, but the gain was “rapidly lost” after stopping [Human RCT] (Falutz 2010). Its label covers HIV-associated abdominal fat only and states it is “not indicated for weight loss management” (Egrifta WR label). It is set against other growth-hormone peptides in ipamorelin vs sermorelin vs tesamorelin.
Light tolerance in a skin disease (afamelanotide). In erythropoietic protoporphyria, a skin disease in which sunlight exposure causes severe pain, afamelanotide implants raised median pain-free time in direct sun to 69.4 hours versus 40.8 hours on placebo in the US trial, and cut phototoxic reactions from 146 to 77 in the European one [Human RCT, n=94 and 74] (Langendonk 2015). FDA approved it in 2019 for adults with this condition (Scenesse label).
Sexual desire (bremelanotide). In two phase 3 trials of 1,267 premenopausal women with low sexual desire disorder, bremelanotide raised desire scores by 0.35 points and lowered related distress by 0.33 points versus placebo [Human RCT] (Kingsberg 2019). It is approved only for premenopausal women, “Not indicated … in men” (Vyleesi label); the evidence is compared with kisspeptin in PT-141 vs kisspeptin.
Collagen peptides: supplement-level benefits
Collagen peptides are taken by mouth, and several randomized trials report benefits. In 69 women aged 35 to 55, eight weeks of collagen hydrolysate improved skin elasticity compared with placebo, with no side effects noted [Human RCT] (Proksch 2014). An 11-trial meta-analysis of 870 people with knee osteoarthritis found better pain and function scores with oral collagen, though results varied widely between trials [Meta-analysis of RCTs] (Simental-Mendía 2025). Not every trial is positive: in 167 active middle-aged and older adults, 12 weeks of collagen peptides did not reduce knee pain [Human RCT] (Bongers 2020). Collagen products are sold as dietary supplements, and FDA “does not have the authority to approve dietary supplements before they are marketed” (FDA).
Research peptides: what the evidence shows so far
BPC-157. The animal record is encouraging: a 2025 systematic review found that in preclinical models BPC-157 “improved functional, structural, and biomechanical outcomes in muscle, tendon, ligament, and bony injuries” [Animal] (Vasireddi 2025). Of the 36 studies it included, 35 were preclinical, and it found “No clinical safety data”. The one human report is a chart review in which 11 of 12 patients given BPC-157 knee injections reported improvement, with no control group [Human case series, n=16] (Lee 2021). Three trials are registered on ClinicalTrials.gov, and none has posted results (NCT02637284, NCT07752381, NCT07803250). Its tissue-repair evidence is ranked against other peptides in best-researched peptides for injury and tendon healing.
TB-500. In 32 rats with Achilles tendon injuries, TB-500 raised the load the healed tendon could bear, and combining it with BPC-157 added no benefit over either alone [Animal] (Biçer 2026). FDA’s Category 2 entry for the fragment states FDA “has not identified any human exposure data” (FDA). The two are compared in BPC-157 vs TB-500.
MOTS-c. In mice, MOTS-c “prevented age-dependent and high-fat-diet-induced insulin resistance, as well as diet-induced obesity” [Animal] (Lee 2015). No trial of MOTS-c itself is registered; the only registered trial tested an analog, CB4211, and posted no results (NCT03998514).
GHK-Cu. The copper peptide is used on the skin. In a small trial after laser resurfacing, objective measures showed no difference in redness, wrinkles or skin quality, although patients using GHK-Cu rated their skin better (P = .04) [Human RCT, 13 completed] (Miller 2006). Its hair evidence is set out in GHK-Cu vs minoxidil for hair.
Thymosin alpha-1. This immune peptide reached a large phase 3 trial, which is a strength, but in 1,106 adults with sepsis 28-day deaths were 23.4% with thymosin alpha-1 and 24.1% with placebo, no statistically significant difference (P=0.93) [Human RCT] (Wu 2025).
Side effects and risks
Approved peptide drugs carry known, labelled risks. Wegovy has a boxed warning because semaglutide caused thyroid C-cell tumors in rodents, and it is not for people with a personal or family history of medullary thyroid cancer (Wegovy label); in SELECT, 16.6% stopped semaglutide for adverse events versus 8.2% on placebo (Lincoff 2023). Forteo’s label warns about osteosarcoma in people at higher risk (Forteo label). Bremelanotide caused nausea in 40% of patients, leading 8% to stop (Vyleesi label). Scenesse lists implant-site reactions, nausea and skin darkening among common effects (Scenesse label).
Research peptides carry unknowns rather than measured risks. FDA lists possible immunogenicity and “peptide-related impurities” for compounded BPC-157 (FDA), and a 2025 review found no clinical safety data (Vasireddi 2025). Products sold as “research use only” are a separate problem: in August 2026 FDA told one seller that its semaglutide, PT-141 and tesamorelin products were “unapproved new drugs” despite their research labels (FDA warning letter). More on these risks is in are peptides safe?
Anyone who suspects a side effect from a peptide or any other drug or product can report it to the FDA through MedWatch.
Legal status and sport
Each approved drug is available on prescription for its labelled use. BPC-157, TB-500 and MOTS-c were withdrawn from FDA’s Category 2 list by their nominators (FDA), and an FDA advisory committee reviewed them for the 503A compounding list on July 23–24, 2026 (FDA); trade press reported votes in favor, which are non-binding, and FDA has issued no rule. What that vote means in practice is covered in FDA peptide compounding vote. For athletes, the 2026 WADA List bans BPC-157 under S0, TB-500 and tesamorelin under S2, and MOTS-c under S4, all at all times (WADA 2026); USADA notes GLP-1 drugs “are not prohibited in sport” (USADA). From January 1, 2027, the List names “peptides” in general under S0 (USADA).
What users report
What follows summarizes unverified self-reports from people who usually bought unregulated products; it is not evidence and has not been checked. People who post about research peptides on Reddit, YouTube and biohacking forums most often describe faster recovery from injuries, less joint pain, better sleep, fat loss and better skin, and many say they noticed changes within a few weeks. They often credit several peptides at once, which makes any single effect impossible to judge. Recurring complaints include nausea and reduced appetite with GLP-1-type products, redness or soreness where products were given, headaches, flushing, tiredness and, for some, no noticeable effect at all. Cost is a frequent topic, and many posters doubt product purity and dosing accuracy because they had no way to test what they bought. Arguments center on whether animal results apply to people, whether peptides are safer than steroids, and whether newer regulatory moves will change access.
Frequently asked questions
Are peptides like Ozempic?
Ozempic is a peptide: its active ingredient, semaglutide, is a GLP-1 peptide drug, and so is Wegovy. Most “peptides” sold online are different, unapproved substances such as BPC-157. Semaglutide has large trials behind it, including SELECT, where 6.5% of patients on it had a heart attack, stroke or cardiovascular death versus 8.0% on placebo.
Are peptides worth taking?
It depends on the peptide and the goal, and a clinician is the person to decide. Approved peptide drugs have proven benefits for specific conditions, such as fewer spine fractures with teriparatide. Most research peptides have only animal data: a 2025 review of BPC-157 found 35 of 36 studies were preclinical and no clinical safety data.
What are the side effects of taking peptides?
Side effects depend on the peptide. Approved drugs list them on their labels: nausea affected 40% of women on bremelanotide, and semaglutide carries a boxed warning about thyroid tumors seen in rodents. For research peptides, side effects in people are largely unknown, and FDA has flagged immunogenicity and impurity risks for compounded BPC-157.
Are peptides safer than steroids?
No general answer exists, because “peptides” covers both tested drugs and untested research chemicals. Approved peptide drugs have known risks listed on their labels. Research peptides such as BPC-157 have no clinical safety data, according to a 2025 review. For athletes, many research peptides are banned at all times: BPC-157 under S0 and TB-500 under S2 of the 2026 WADA List.
References
- Wilding JPH, Batterham RL, Calanna S, et al. 2021. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. PubMed 33567185
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. 2023. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. PubMed 37952131
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. 2022. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. PubMed 35658024
- Neer RM, Arnaud CD, Zanchetta JR, et al. 2001. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. PubMed 11346808
- Falutz J, Potvin D, Mamputu JC, et al. 2010. Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation. J Acquir Immune Defic Syndr. PubMed 20101189
- Langendonk JG, Balwani M, Anderson KE, et al. 2015. Afamelanotide for erythropoietic protoporphyria. N Engl J Med. PubMed 26132941
- Kingsberg SA, Clayton AH, Portman D, et al. 2019. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. PubMed 31599840
- Proksch E, Segger D, Degwert J, et al. 2014. Oral supplementation of specific collagen peptides has beneficial effects on human skin physiology. Skin Pharmacol Physiol. PubMed 23949208
- Simental-Mendía M, Ortega-Pierres D, Sánchez-García A, et al. 2025. Effect of collagen supplementation on knee osteoarthritis: an updated systematic review and meta-analysis. Clin Exp Rheumatol. PubMed 39212129
- Bongers CCWG, Ten Haaf DSM, Catoire M, et al. 2020. Effectiveness of collagen supplementation on pain scores in healthy individuals with self-reported knee pain. Appl Physiol Nutr Metab. PubMed 31990581
- Wu J, Pei F, Zhou L, et al. 2025. The efficacy and safety of thymosin α1 for sepsis (TESTS). BMJ. PubMed 39814420
- Miller TR, Wagner JD, Baack BR, et al. 2006. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. PubMed 16847171
- Vasireddi N, Hahamyan H, et al. 2025. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. PubMed 40756949
- Lee E, Padgett B. 2021. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. PubMed 34324435
- Biçer O, et al. 2026. BPC-157, TB-500 and their combination in rat Achilles tendon healing. Jt Dis Relat Surg. PubMed 42542926
- Lee C, Zeng J, Drew BG, et al. 2015. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. PubMed 25738459
- US FDA. Wegovy (semaglutide) prescribing information. DailyMed
- US FDA. FDA approves new medication for chronic weight management (Zepbound), November 8, 2023. FDA
- US FDA. Forteo (teriparatide) prescribing information. DailyMed
- US FDA. Egrifta WR (tesamorelin) prescribing information (03/2025). DailyMed
- US FDA. Scenesse (afamelanotide) prescribing information (published 2026-05-13). DailyMed
- US FDA. Vyleesi (bremelanotide) prescribing information. DailyMed
- US FDA. Questions and answers on dietary supplements. FDA
- US FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (content current 2026-04-22). FDA
- US FDA. July 23–24, 2026 meeting of the Pharmacy Compounding Advisory Committee (content current 2026-08-06). FDA
- US FDA. Warning letter to Peak Performance Peptides, MARCS-CMS 735127, August 24, 2026. FDA
- ClinicalTrials.gov. NCT02637284: PCO-02, safety and pharmacokinetics trial. ClinicalTrials.gov
- ClinicalTrials.gov. NCT07752381: A clinical trial to evaluate the effects of peptide gummies on markers of inflammation, physical performance, and recovery. ClinicalTrials.gov
- ClinicalTrials.gov. NCT07803250: Impact of BPC-157 on recovery following rotator cuff repair surgery. ClinicalTrials.gov
- ClinicalTrials.gov. NCT03998514: A phase 1a/1b study of CB4211 in healthy non-obese subjects and subjects with nonalcoholic fatty liver disease. ClinicalTrials.gov
- World Anti-Doping Agency. 2026 Prohibited List, in effect 1 January 2026. WADA
- US Anti-Doping Agency. Athlete advisory: what’s new on the 2027 WADA Prohibited List? usada.org
- US Anti-Doping Agency. BPC-157: prohibited peptide. usada.org
- US Anti-Doping Agency. Weight loss drugs: what athletes need to know about GLP-1s. usada.org
Change log
2026-10-26: links to related entries added; no change to the facts.
2026-10-19: links to related entries added; no change to the facts.
2026-10-18: removed ClinicalTrials.gov records NCT07437547 and NCT07505745, whose sponsor posts example records; BPC-157 now lists its 3 registered trials (none with posted results) and MOTS-c only the completed trial of its analog CB4211; reviewed by the editorial team.
2026-10-15: first published after review by the editorial team.